Tenax Therapeutics Inc.
(NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). • Tenax Therapeutics stock is testing lower boundaries.
Why is TENX stock at lows?
PH-HFpEF is a complex condition where stiffening of the left side of the heart causes blood to back up into the lungs, raising pressure in the pulmonary blood vessels even though the heart's pumping capacity remains normal.
Read Also: Edgewise Therapeutics Reports Improvements In Heart Drug Trial Although the trial missed its primary endpoint for exercise capacity improvement and its key secondary symptom score target, the company plans to request a Type C meeting with the U.S.
